Filing Information

Inventor(s)	Keith Coupland · Yann Raoul ·
Assignee(s)	Croda International PLC ·  View assignee updates
Attorney/Agent(s)	Stevens, Davis, Miller & Mosher, L.L.P. ·
Primary Examiner	Deborah Carr ·
Application Number	US10130672
Filing date	08/19/2002
PCT 371 date	08/19/2002
Issue date	12/16/2003
Predicted expiration date	08/19/2022
U.S. Classifications	554/225  · 514/838  · 554/168  · 514/558  · 514/560  · 514/825  · 554/159  · 514/861  · 514/885  · 514/886  · 514/912  · 514/894  · 554/227  ·
International Classifications	--
Kind Code	B1
International Classifications	589159 · 589168 · 589227 · 514558 · 514828 · 514838 · 514861 · 514888 · 514884 · 514912 ·
Related U.S. Application Data	This application is a 371 of PCT/GB00/04453 filed Nov. 23, 2000.
PCT Application Number	WO20PCTGB0004453 - 11/23/2000
PCT Publication Number	WO200138288 - 05/31/2001
Foreign Priority	GB9927629 - 11/24/1999 ·

Patent Family

Abstract

The present invention relates to a nervonic acid derivatives of formula (I) CH3—(CH2)7—CHCH—(CH2)13—C(O)—O—(CH2)3—OR  (I) wherein R is hydrogen (H) or a residue of a carboxylic acid; or a salt of the compound where R is H; or a bioprecursor, prodrug thereof. Those compounds wherein R is other than H have pharmacological activity, in particular anti-inflammatory and immunomodulatory effects. Those compounds wherein R is H can be used to prepare the pharmacologically active derivatives.

Independent Claims | See all claims (29)

1. 1. A compound of formula (I): CH3—(CH2)7—CHCH—(CH2)13—C(O)—O—(CH2)3—OR  (I) wherein R is a compound selected from the group consisting of hydrogen (H) and a residue of a carboxylic acid; and salts of the compound where R is H; and bioprecursors, prodrugs and hydrates thereof.
2. 6. A compound selected from the group consisting of: 1-(z-15-tetracosenoyloxy)-3-hydroxypropane; 1-(z-15-tetracosenoyloxy)-3-(z,z,z-6,9,12-octadecatrienoyloxy)propane (hereinafter referred to as NA:GLA); 1-(z-15-tetracosenoyloxy)-3-(z,-4,7,10,13,16,19-docosahexaenoyloxy)propane (hereinafter referred to as NA:DHA); and 1,3-di-(z-15-tetracosenoyloxy)propane (hereinafter referred to as NA:NA).